Being tested
Immune reconstitution (cladribine, alemtuzumab, aHSCT): slow disability worsening in secondary progressive MS
secondary progressive MS · Immune reconstitution (cladribine, alemtuzumab, aHSCT)
Trials are running now and no controlled trial has a readable result yet.
- Trials
- 2
- Running now
- 1
- Controlled phase 2/3 trials
- 1
- People in controlled trials
- 204
No controlled trial has reported a result yet.
Other linked trials: 2
Dose comparisons, trials against another medicine, add-on trials, phase 1 and uncontrolled studies. They are listed below but do not set the status.
Trials
Other linked trials: 2
These linked trials do not set the status.
- A Prospective Biomarker Study in Active SPMS Subjects Treated With Cladribine TabletsNo result found
Phase 4 · 2020 · Not randomised
- ChariotMSOngoing
Phase 2/3 · 2021 · Placebo-controlled
The deciding phase and counts come from the Trial Bank’s fixed rules.
Lab evidence
Lab studies in animals or cells. Results in animals often do not hold in people, and these studies never change the status of an idea.
Loading lab studies…
Loading reviews and guidelines…
History
- 2026-10-28Trials: 1 → 2
- 2026-10-28Status changed from No clear answer to Being tested
- 2026-10-27First listed as No clear answer
Related hypotheses
- Immune reconstitution (cladribine, alemtuzumab, aHSCT): slow disability worsening in early MS (CIS or RIS)
- Immune reconstitution (cladribine, alemtuzumab, aHSCT): slow disability worsening in primary progressive MS
- Immune reconstitution (cladribine, alemtuzumab, aHSCT): slow disability worsening in relapsing MS
- Immune reconstitution (cladribine, alemtuzumab, aHSCT): slow disability worsening in relapsing and progressive MS
- Immune reconstitution (cladribine, alemtuzumab, aHSCT): slow disability worsening in MS (type not specified)
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error